Webinars Overview
Peptide therapeutics offer immense potential but present complex development challenges, particularly in oral formats. This expert-led presentation explores how integrated DMPK, bioanalytical, and toxicology strategies can address barriers to absorption, stability, and safety. With a focus on practical case examples and proven approaches, it highlights how thoughtful study design and cross-functional expertise can streamline development and reduce risk from early studies through clinical advancement.
Learning Objectives:
- Understand key DMPK challenges for peptide therapeutics, including absorption barriers and formulation impact. 
- Explore bioanalytical strategies for accurate peptide quantification, immunogenicity, and metabolite analysis. 
- Learn how peptide toxicology differs from small molecules and how to design effective safety studies. 
- Discover how integrated DMPK, bioanalysis, and toxicology approaches streamline development and reduce risk. 
- Gain insights from real-world case examples to support smarter study design and regulatory readiness. 
Related Resources
- 
                                
                                        Decoding Peptide ADME Challenges: Integrated Radiolabeled Synthesis & ADME Platform - DMPK FrontiersVideosOct 24,2025
- 
                                
                                        In Vitro Metabolic Stability of Peptide Drugs Across Different TissuesArticlesSep 30,2025
- 
                                
                                        Biomimetic Chromatography Method to Estimate Human Plasma Protein Binding for PeptidesPostersSep 19,2025
Related Services and Platforms
Stay Connected
Keep up with the latest news and insights.
 
                        
                         
                     
                                                             
                                                         
                                     
                                     
                                     
                                         
                                     
                                     
                                     
                                     
                                     
                                     
                                    